| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(26 days from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(4 years from now) | |
|
US7932241 (Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(4 years from now) | |
Reclast is owned by Novartis.
Reclast contains Zoledronic Acid.
Reclast has a total of 3 drug patents out of which 0 drug patents have expired.
Reclast was authorised for market use on 16 April, 2007.
Reclast is available in injectable;intravenous dosage forms.
Reclast can be used as treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis.
The generics of Reclast are possible to be released after 05 August, 2028.
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
RECLAST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic